Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E: International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007, 370: 741-750. 10.1016/S0140-6736(07)61377-4.
Article
PubMed
Google Scholar
Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007, 356: 775-789. 10.1056/NEJMoa063070.
Article
CAS
PubMed
Google Scholar
Gan WQ, Man SP, Sin D: Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med. 2005, 5: 3-10.1186/1471-2466-5-3.
Article
PubMed
PubMed Central
Google Scholar
Jen R, Rennard SI: Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. International Journal of Chronic Pulmonary Obstructive Disease. 2012, 7: 587-595.
CAS
Google Scholar
Barnes PJ: New Concepts in Chronic Obstructive Pulmonary Disease. Annu Rev Med. 2003, 54: 113-129. 10.1146/annurev.med.54.101601.152209.
Article
CAS
PubMed
Google Scholar
Culpitt SV, Rogers DF, Shah P, De Matos C, Russell REK, Donnelly LE, Barnes PJ: Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2003, 167: 24-31. 10.1164/rccm.200204-298OC.
Article
PubMed
Google Scholar
Adcock IM, Barnes PJ: Molecular mechanisms of corticosteroid resistance. Chest. 2008, 134: 394-401. 10.1378/chest.08-0440.
Article
CAS
PubMed
Google Scholar
Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK: Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2003, 168: 976-982. 10.1164/rccm.200212-1490OC.
Article
PubMed
Google Scholar
Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009, 374: 695-703. 10.1016/S0140-6736(09)61252-6.
Article
CAS
PubMed
Google Scholar
Calverley PM, Rabe KF, Goehring U, Kristiansen S, Fabbri LM, Martinez FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009, 374: 685-694. 10.1016/S0140-6736(09)61255-1.
Article
CAS
PubMed
Google Scholar
Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003, 2: 717-726. 10.1038/nrd1177.
Article
CAS
PubMed
Google Scholar
Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R: A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients. J Clin Pharmacol. 2010, 50: 94-100. 10.1177/0091270009347873.
Article
CAS
PubMed
Google Scholar
Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R: on behalf of the Losmapimod Study Investigators: An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. J Clin Pharmacol. 2012, 52: 416-424. 10.1177/0091270010397050.
Article
CAS
PubMed
Google Scholar
Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, Donnelly LE: Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol. 2006, 149: 393-404. 10.1038/sj.bjp.0706885.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kent LM, Smyth LJ, Plumb J, Clayton CL, Fox SM, Ray DW, Farrow SN, Singh D: Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther. 2009, 328: 458-468. 10.1124/jpet.108.142950.
Article
CAS
PubMed
Google Scholar
Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002, 57: 759-764. 10.1136/thorax.57.9.759.
Article
CAS
PubMed
PubMed Central
Google Scholar
Keatings V, Collins P, Scott D, Barnes P: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996, 153: 530-534.
Article
CAS
PubMed
Google Scholar
Wedzicha JA, Seemungal TAR, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW: Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels. Thromb Haemost. 2000, 84: 210-215.
CAS
PubMed
Google Scholar
Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP: Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J. 2008, 31: 1005-1012. 10.1183/09031936.00100307.
Article
CAS
PubMed
Google Scholar
He J, Foreman MG, Shumansky K, Zhang X, Akhabir L, Sin DD, Man SFP, DeMeo DL, Litonjua AA, Silverman EK, Connett JE, Anthonisen NR, Wise RA, Paré PD, Sandford AJ: Associations of IL6 polymorphisms with lung function decline and COPD. Thorax. 2009, 64: 698-704. 10.1136/thx.2008.111278.
Article
PubMed
PubMed Central
Google Scholar
Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A: In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors. Br J Pharmacol. 1997, 121: 221-231. 10.1038/sj.bjp.0701124.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hatzelmann A, Schudt C: Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro. J Pharmacol Exp Ther. 2001, 297: 267-279.
CAS
PubMed
Google Scholar
Armstrong J, Sargent C, Singh D: Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol. 2009, 158: 74-83. 10.1111/j.1365-2249.2009.03986.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M: Increased activation of p38 MAPK in COPD. Eur Respir J. 2008, 31: 62-69. 10.1183/09031936.00036707.
Article
CAS
PubMed
Google Scholar
Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A, Lewthwaite RA, Mahnke A, Mathias JP, Philip J, Smith RT, Stefaniak MH, Yeadon M, Phillips C: Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem. 2011, 54: 7797-7814. 10.1021/jm200677b.
Article
CAS
PubMed
Google Scholar
Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF: Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010, 35: 750-756. 10.1183/09031936.00071309.
Article
CAS
PubMed
Google Scholar
Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D: Syngergistic effects of p38 mitogen activated protein kinase inhibition with a corticosteroid in Alveolar Macrophages from patients with Chronic Obstructive Pulmonary Disease. J Pharmacol Exp Ther. 2011, 338: 732-10.1124/jpet.111.180737.
Article
CAS
PubMed
Google Scholar